Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.

ABSTRACT:

Purpose

Evidence about routine treatment and outcome of patients with invasive lobular cancer (ILC) is limited, especially regarding metastatic disease. Here we present prospective real-world data of patients with metastatic ILC (mILC) as compared to patients with metastatic invasive ductal cancer (mIDC) receiving systemic therapy in routine care in Germany.

Methods

Prospective data on patient and tumor characteristics, treatments, and outcomes of patients with mILC (n = 466) and mIDC (n = 2100), recruited between 2007 and 2021 into the Tumor Registry Breast Cancer/OPAL were analyzed.

Results

Compared to mIDCs, patients with mILC were older at start of first-line treatment (median 69 vs. 63 years) and had more often lower grade (G1/G2: 72.8% vs. 51.2%), hormone recept

SUBMITTER: Thill M 

PROVIDER: S-EPMC10036409 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature